China Pharma Holdings, Inc. expects to launch its Dry Eye Disease Therapeutic Device in the first quarter of 2025

Company Overview - China Pharma Holdings, Inc. is a specialty pharmaceutical company listed on NYSE American, focusing on high-incidence and high-mortality conditions in China, including cardiovascular, CNS, infectious, and digestive diseases [4] - The company operates a cost-effective business model driven by market demand, supported by GMP-certified product lines and a broad distribution network across major cities and provinces in China [4] Product Launch - The company plans to launch its Dry Eye Disease Therapeutic Device in the first quarter of 2025 through its wholly-owned subsidiary, Hainan Helpson Medical and Biotechnology Co., Ltd. [1] - The device is designed for treating dry eye disease and is under patent protection; the technology was acquired at the end of 2022, and the company has completed production commissioning and third-party testing [1] Market Opportunity - The incidence of dry eye disease in China is approximately 21%-30%, with nearly 400 million patients in a total population of about 1.4 billion [2] - The Chinese dry eye disease market is projected to grow at a CAGR of 6.04% from 2023 to 2030, reaching a market size of $579.51 million by 2030, driven by increased electronic product usage and an aging population [2] Treatment Technology - The therapeutic device utilizes an ophthalmic oxygen-enriched atomization technology that sprays tiny oxygen-rich droplets into the eyes, enhancing moisture and oxygen supply to the eye surface [3] - This physical therapy approach aims to improve the quality and stability of tear fluid while avoiding potential side effects associated with drug treatments, thereby enhancing treatment effectiveness and comfort [3]